Key result
Higher vitamin D levels linked to ~2% lower all-cause mortality in CKM syndrome.
Why the study?
Do higher serum 25-hydroxyvitamin D levels reduce all-cause and cardiovascular disease mortality in adults with CKM syndrome stages 0-3?
Cohort (n=37,551)
Yes
Do higher serum 25-hydroxyvitamin D levels reduce all-cause and cardiovascular disease mortality in adults with CKM syndrome stages 0-3?
Hazard Ratio: 0.98 (95% CI 0.97–0.99)
p-value: p=<0.001
In US adults with CKM syndrome stages 0-3, serum 25(OH)D levels above approximately 52-54 nmol/L are associated with a small but significant reduction in all-cause and cardiovascular mortality.
BACKGROUND: The association between vitamin D status and mortality risk among adults with cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3 requires further elucidation. We investigated the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and all-cause and cause-specific mortality among United States adults diagnosed with CKM syndrome stages 0–3. METHODS: Data from 37,551 adults presenting with CKM syndrome stages 0–3 were examined using National Health and Nutrition Examination Survey records (2001–2018). Death outcomes were determined via National Death Index linkage through December 31, 2019. Cox proportional hazards modeling and two-piecewise Cox regression approaches were utilized to assess nonlinear relationships between serum 25(OH)D levels and mortality risk, incorporating stratified analyses for high-risk population identification. RESULTS: Throughout 337,921 person-years of observation, we documented 4,039 deaths from all causes, encompassing 1,078 cardiovascular disease (CVD)-related deaths. Following multivariable adjustment, reduced serum 25(OH)D levels demonstrated significant associations with elevated all-cause and CVD mortality risk through nonlinear patterns. L-shaped dose-response curves emerged, revealing mortality risk plateaus at 52.20 nmol/L for all-cause mortality and 53.90 nmol/L for CVD mortality. Individuals maintaining 25(OH)D levels above these threshold values exhibited 2% reduced all-cause mortality risk (hazard ratio [HR] 0.98, 95% confidence interval [CI] 0.97–0.99) and 2% decreased CVD mortality risk (HR 0.98, 95% CI 0.97–0.99) relative to participants below these cutoff points. CONCLUSIONS: Nonlinear relationships between serum 25(OH)D levels and both all-cause and CVD mortality were demonstrated among United States adults with CKM syndrome stages 0–3. These findings warrant confirmation through randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) conducted a cohort in Cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 (n=37,551). Serum 25-hydroxyvitamin D [25(OH)D] levels vs. Lower serum 25(OH)D levels (below 52.20 nmol/L) was evaluated on All-cause mortality (HR 0.98, 95% CI 0.97-0.99, p=<0.001). Maintaining serum 25-hydroxyvitamin D levels above 52.20 nmol/L was associated with a 2% reduced risk of all-cause mortality (HR 0.98) compared to levels below this threshold in adults with CKM syndrome stages 0-3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: